[Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy].
The present study was designed to elucidate the effect of cimetidine and PSK on T-cell subsets, interleukin-2 (IL-2) production and its receptor in peripheral blood lymphocytes (PBL) from patients with advanced ovarian carcinoma during the course of chemotherapy. Preoperative levels of OKT 4/8 cell ratio and IL-2 production in PBL from patients with advanced ovarian carcinoma were significantly lower than those with benign ovarian tumor. When a combination chemotherapy which consisted of cisplatin, adriamycin and cyclophosphamide was given to these ovarian cancer patients, the OKT 4/8 cell ratio was significantly increased while the IL-2 production was markedly inhibited. When PSK and cimetidine were combined with the combination chemotherapy, the inhibition of IL-2 production was reduced. When treatment with PSK or cimetidine was initiated after completion of the combination chemotherapy, the OKT 4/8 cell ratio was significantly elevated on 30 days and 60 days, compared to 7 days after the completion of chemotherapy. The depressed IL-2 production after completion of the combination chemotherapy was increased to about 8 times by cimetidine and about 2.5 times by PSK on 60 days after completion of chemotherapy. On the other hand, the IL-2 receptor remained unchanged even if PSK or cimetidine was administered.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology*; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology*; D011509:Proteoglycans / Q000008:administration & dosage / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000145:classification
D007376:Interleukin-2; D011509:Proteoglycans; C010770:polysaccharide-K; D002927:Cimetidine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin